Volixibat is an IBAT inhibitor, meaning that it blocks the function of the IBAT protein (ileal bile acid transporter), which is also called SLC10A2 (solute carrier family 10 member 2) or ASBT …

Volixibat is an oral, minimally absorbed agent designed to selectively inhibit the ileal bile acid transporter (IBAT). Volixibat may offer a novel approach in the treatment of adult cholestatic …

2012年2月1日 · Volixibat (SHP626 or LUM002, developed by Shire) is a highly selective, minimally absorbed ASBT inhibitor. It significantly increased the total amount of BAs in feces, …

Volixibat is an inhibitor of the apical sodium-dependent bile acid transporter (ASBT) that has been hypothesized to improve non-alcoholic steatohepatitis (NASH) by blocking bile acid reuptake …

2024年6月17日 · An oral ileal bile acid transporter (IBAT) inhibitor, volixibat is a minimally absorbed agent potentially offering a novel approach in the treatment of adult cholestatic …

2024年10月10日 · Volixibat, an oral IBAT inhibitor, offers a novel approach to treating adult cholestatic diseases by reducing systemic and liver bile acids. VANTAGE trial showed …

Volixibat is a selective inhibitor of the apical sodium-dependent bile acid transporter (ASBT), a transmembrane protein primarily expressed by enterocytes of the ileum. ASBT is primarily …

What is Volixibat and how does it work? Volixibat is an investigational drug that works as an Ileal Bile Acid Transporter (IBAT) inhibitor. It is designed to reduce bile acid levels in the body, …

Volixibat is a selective inhibitor of the apical sodium-dependent bile acid transporter (ASBT), a transmembrane protein primarily expressed by enterocytes of the ileum. Also known as the …

Volixibat (SHP626) is a highly selective, minimally absorbed, and competitive apical sodium-dependent bile acid transporter (ASBT) inhibitor. Volixibat has potential for treatment for non …